During the past decade, Samsung Medical Center, Sungkyunkwan University School of Medicine conducted 39 clinical trials. In the 10-year time frame, 39 clinical trials started and 5 clinical trials were completed, i.e. on average, 12.8% percent of trials that started reached the finish line to date. In the past 5 years, 14 clinical trials started and 2 clinical trials were completed. i.e. 14.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Samsung Medical Center, Sungkyunkwan University School of Medicine" #1 sponsor was "Samsung Medical Center" with 36 trials, followed by "Hoffmann-La Roche" with 5 trials sponsored, "Pfizer" with 4 trials sponsored, "Asan Medical Center" with 3 trials sponsored and "Kangbuk Samsung Hospital" with 3 trials sponsored. Other sponsors include 13 different institutions and companies that sponsored additional 20 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Samsung Medical Center, Sungkyunkwan University School of Medicine" #1 collaborator was "Inje University" with 3 trials as a collaborator, "Keimyung University Dongsan Medical Center" with 2 trials as a collaborator, "Korea University Guro Hospital" with 2 trials as a collaborator, "Korean Cancer Study Group" with 2 trials as a collaborator and "Samsung Medical Center" with 2 trials as a collaborator. Other collaborators include 31 different institutions and companies that were collaborators in the rest 39 trials.

According to Clinical.Site data, the most researched conditions in "Samsung Medical Center, Sungkyunkwan University School of Medicine" are "Atrial Fibrillation" (3 trials), "Interstitial Cystitis" (3 trials), "Non-small Cell Lung Cancer (NSCLC)" (3 trials), "Stroke" (3 trials) and "Benign Prostatic Hyperplasia (BPH)" (2 trials). Many other conditions were trialed in "Samsung Medical Center, Sungkyunkwan University School of Medicine" in a lesser frequency.

Most popular intervention types in "Samsung Medical Center, Sungkyunkwan University School of Medicine" are "Drug" (34 trials), "Procedure" (8 trials), "Device" (6 trials), "Other" (6 trials) and "Diagnostic Test" (3 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab" (4 trials), "Placebo" (4 trials), "Carboplatin" (3 trials), "AZD9291" (2 trials) and "Cisplatin" (2 trials). Other intervention names were less common.

The vast majority of trials in "Samsung Medical Center, Sungkyunkwan University School of Medicine" are 61 trials for "All" genders, 6 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Samsung Medical Center, Sungkyunkwan University School of Medicine". undefined are not yet recruiting, 10 are recruiting, 6 are Active, not recruiting, and 3 are Enrolling by invitation. In total, there were 30 completed trials in Samsung Medical Center, Sungkyunkwan University School of Medicine, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Samsung Medical Center, Sungkyunkwan University School of Medicine, 1 "Phase 1" clinical trials were conducted, 13 "Phase 2" clinical trials and 11 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 11 trials that are defined as “Not Applicable".